Clinical Trials Logo

Recurrent Disease clinical trials

View clinical trials related to Recurrent Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03792256 Active, not recruiting - Acute Leukemia Clinical Trials

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Start date: April 11, 2019
Phase: Phase 1
Study type: Interventional

AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are most commonly treated with ALL regimens. The proposed palbociclib starting dose for this study will be 50 mg/m^2/day for 21 days.